Loading...
XPAR
AMPLI
Market cap342mUSD
Oct 09, Last price  
6.25EUR
Name

Amplitude Surgical SA

Chart & Performance

D1W1MN
XPAR:AMPLI chart
P/E
196.23
P/S
2.83
EPS
0.03
Div Yield, %
Shrs. gr., 5y
0.07%
Rev. gr., 5y
0.67%
Revenues
106m
+5.81%
047,249,00050,268,00058,228,00071,090,00080,788,00093,356,000100,336,000102,559,00088,286,00082,713,00087,559,000100,200,000106,019,000
Net income
2m
-96.11%
-2,266,000-2,017,000-2,149,000-2,846,000-17,646,000219,000-12,052,000-9,446,000-8,989,000-14,198,000-14,099,000-4,392,00039,246,0001,528,000
CFO
4m
-50.06%
-3,399,000-3,264,000197,000-1,953,000-16,530,0001,987,0002,680,0008,981,0008,242,00012,384,0002,344,0007,983,0008,096,0004,043,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Amplitude Surgical S.A. specializes in the design, development, and commercialization of surgical solutions for orthopedics. Its comprehensive portfolio addresses both primary and revision procedures, targeting a variety of conditions affecting the hip, knee, and lower limbs, with a particular focus on foot and ankle pathologies. This includes a wide array of knee and hip prostheses, as well as specialized implants for the foot and ankle. Beyond implants, Amplitude Surgical offers advanced technological platforms like AMPLIVISION, a computer-aided surgical system; i.M.A.G.E., a customized, single-use instrumentation solution; and E.T.O.I.L.E., an innovative platform facilitating less-invasive anterior surgical approaches. The company also supplies the necessary instrumentation for implant fitting. Operating globally, its products reach approximately 30 countries through an extensive network of distributors and agents, serving patients, surgeons, and healthcare institutions. Established in 1997, Amplitude Surgical S.A. maintains its headquarters in Valence, France.
IPO date
Jun 26, 2015
Employees
489
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT